S&P Biotech EFT (XBI) Pops on Amylin (AMLN) Buyout News
Tweet
Share
E-mailGet Alerts AMLN Hot Sheet
Join SI Premium – FREE
Shares of Amylin (Nasdaq: AMLN) moved higher by 9 percent today after reports came out that the company will be acquired at $31 per share by Bristol-Myers (NYSE: BMY). Amylin Pharmaceuticals Inc is a 4.6 percent weighting in S&P Biotech EFT (NYSE: XBI).
Other companies in the sector are also moving higher, including Human Genome Sciences Inc. (Nasdaq: HGSI) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN).
Interest in shares in this sector peaked last week when Arena Pharma (Nasdaq: ARNA) got the green light on its latest drug, Belviq, targeting overweight Americans. Later this month, several other stocks in the biotech space will be making news including Vivus Inc. (Nasdaq: VVUS) and its drug Qnexa, and Amarin Corporation PLC's (Nasdaq: AMRN) and it's drug AMR101.
Other companies in the sector are also moving higher, including Human Genome Sciences Inc. (Nasdaq: HGSI) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN).
Interest in shares in this sector peaked last week when Arena Pharma (Nasdaq: ARNA) got the green light on its latest drug, Belviq, targeting overweight Americans. Later this month, several other stocks in the biotech space will be making news including Vivus Inc. (Nasdaq: VVUS) and its drug Qnexa, and Amarin Corporation PLC's (Nasdaq: AMRN) and it's drug AMR101.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wall Street closes higher as investors digest earnings, megacap outlook
- Evercore ISI Downgrades SunPower (SPWR) to In Line
- Evercore ISI Recaps Verizon Communications (VZ) Earnings
Create E-mail Alert Related Categories
ETFsRelated Entities
Standard & Poor'sSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
